BioNTech Aktie
WKN DE: A2PSR2 / ISIN: US09075V1026
|
08.08.2025 08:13:24
|
BioNTech Reaches Agreement to Receive a Non-exclusive License for mRNA-based COVID-19 and/or Influenza Products and Resolve Patent Litigation with CureVac and GSK
BioNTech SE (Nasdaq: BNTX) is committed to developing breakthrough mRNA-based medicines for those in need. The announced acquisition of CureVac N.V. (Nasdaq: CVAC) (the “Acquisition”) is an investment in the future of mRNA-based cancer medicines and another strategic building block for BioNTech.Weiter zum vollständigen Artikel bei RSS Importer
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu BioNTech (ADRs)mehr Nachrichten
Analysen zu BioNTech (ADRs)mehr Analysen
| 22.08.25 | BioNTech Neutral | UBS AG | |
| 05.08.25 | BioNTech Buy | Deutsche Bank AG | |
| 05.08.25 | BioNTech Neutral | UBS AG | |
| 05.08.25 | BioNTech Buy | Jefferies & Company Inc. | |
| 13.06.25 | BioNTech Buy | Deutsche Bank AG |
Aktien in diesem Artikel
| BioNTech (ADRs) | 90,05 | -1,42% |
|
| CureVac | 4,61 | 0,22% |
|
| GSK PLC Sponsored American Depositary Recepit Repr Shs When Issued | 40,60 | 4,10% |
|